High-dose Vitamin D Supplementation for ADT-induced Side Effects
2019年4月4日 更新者:Luke Peppone、University of Rochester
The purpose of this study is to test the efficacy of a high-dose vitamin D supplementation regimen in reducing androgen deprivation therapy (ADT)-related side effects in older prostate cancer patients on ADT.
The proposed study is a randomized, double-blind, 2-arm, controlled clinical trial that will accrue 76 prostate cancer patients without severe bone loss, aged 60 and older, beginning ADT, and scheduled to receive at least 6 months more of ADT.
Participants will be randomized to: 1) weekly high-dose vitamin D3 (50,000 IU) or 2) vitamin D placebo only for a period of 24 weeks.
Both groups will also receive a daily multivitamin and calcium supplement.
研究概览
详细说明
The investigators hypothesize high-dose vitamin D supplementation will reduce androgen deprivation therapy (ADT)-related side effects including ADT-induced bone loss, decreased muscle mass, falls, reduced muscle strength, and diminished physical performance in older prostate cancer patients.
The vitamin D supplementation is aimed at reducing fracture risk by maintaining proper bone density, thereby preventing osteoporotic/osteopenic conditions and increasing muscle mass.
Both vitamin D and exercise are efficacious in maintaining proper bone health and muscle mass among the general population, but little research has been done on prostate cancer patients and survivors.
Vitamin D could reduce fracture risk among prostate cancer survivors.
研究类型
介入性
注册 (实际的)
108
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
New York
-
Rochester、New York、美国、14624
- Wilmot Cancer Center, University of Rochester
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
60年 至 99年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Have a confirmed diagnosis of stage I-IIIA prostate cancer
- Within 6 months of starting ADT with an additional 6 more months planned.
- Participants must have sub-optimal vitamin D levels of <32 ng/ml.
- Participants must agree not to take calcium and/or vitamin D supplements for the duration of the intervention other than those provided.
- Participants must have an ionized serum calcium level within normal limits (1.19-1.29mmol/L) and a total corrected serum calcium of ≤10.5 mg/dl.
- No contraindications for fitness testing and no physical limitations (e.g. cardiorespiratory, orthopedic, nervous system) as assessed by their physician.
- Able to read English (since the assessment materials are in printed format).
- Able to swallow medication and provide written informed consent.
- 60 years of age or older.
Exclusion Criteria:
- Previously verified diagnosis of osteoporosis (any t-score ≤ -2.5).
- Patients on antiresorptive drugs (i.e. bisphosphonates) within the past year.
- Patients with hypercalcemia (corrected serum Ca > 10.5 mg/dl) or a history of hypercalcemia or vitamin D toxicity/sensitivity.
- Patients with impaired renal function (CrCl < 60 mL/min) or who had kidney stones (calcium salt) within the past 5 years.
- Myocardial infarction within the past year.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:Vitamin D3
Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
|
50,000IU/week of vitamin D3
|
安慰剂比较:Control
Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
bone mineral density
大体时间:after 24 weeks
|
mean difference in bone mineral density between treatment group and control group
|
after 24 weeks
|
bone biomarkers
大体时间:after 24 weeks
|
amino-terminal collagen crosslinks (NTx) and bone-specific alkaline phosphatase (BSAP)
|
after 24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
muscle mass
大体时间:after 24 weeks
|
muscle mass as assessed by dual energy x-ray absorptiometry
|
after 24 weeks
|
muscular strength
大体时间:after 24 weeks
|
as assessed by Handgrip Dynamometer and 7-10 Repetition Maximum
|
after 24 weeks
|
physical performance
大体时间:after 24 weeks
|
as assessed by falls, physical performance battery, and 6-min walk test
|
after 24 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Luke J Peppone, PhD, MPH、University of Rochester
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2014年3月1日
初级完成 (实际的)
2016年11月1日
研究完成 (实际的)
2016年11月1日
研究注册日期
首次提交
2014年2月14日
首先提交符合 QC 标准的
2014年2月14日
首次发布 (估计)
2014年2月17日
研究记录更新
最后更新发布 (实际的)
2019年4月8日
上次提交的符合 QC 标准的更新
2019年4月4日
最后验证
2019年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的